| 1 |
NCT03934905 |
Not yet recruiting |
Protective Effects of the Nutritional Supplement Sulforaphane on Doxorubicin-Associated Cardiac Dysfunction |
- Anthracycline Related Cardiotoxicity in Breast Cancer
|
- Drug: sulforaphane
- Drug: Placebo Oral Tablet
|
Interventional
|
Phase 1
Phase 2 |
- Texas Tech University Health Sciences Center
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Prevention
|
- Change in cardiac function after DOX therapy with or without sulforaphane through diagnostic studies
- Elevation of troponin levels as a surrogate evidence of DOX related cardiotoxicity will be checked at baseline, prior to each DOX therapy and then at 1 year from baseline assessment (Each cycle is 14 days).
- Tumor size in patients on DOX therapy with or without sulforaphane treatment will be assessed at baseline, at completion of DOX chemotherapy (4 cycles planned with each cycle being 14 days) and at 1 year from baseline assessment.
|
70 |
All |
18 Years to 89 Years (Adult, Older Adult) |
NCT03934905 |
L19-065 |
|
June 1, 2019 |
June 1, 2021 |
June 1, 2022 |
May 2, 2019 |
May 2, 2019 |
|
- Texas Tech University Health Sciences Center
Lubbock, Texas, United States
|
|
| 2 |
NCT02880462 |
Not yet recruiting |
A 6-month Study to Evaluate Sulforaphane add-on Effects in Treatment of Schizophrenia |
|
- Dietary Supplement: sulforaphane
- Other: placebo
|
Interventional
|
Phase 2
Phase 3 |
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- Cognitive improvement assessed using the MATRICS Consensus Cognitive Battery (MCCB) composite score
- side effects by SAFTEE
- side effects by AIMS
- (and 4 more...)
|
180 |
All |
18 Years to 50 Years (Adult) |
NCT02880462 |
Stanley-Sulforaphane |
|
September 2016 |
December 2019 |
December 2019 |
August 26, 2016 |
August 26, 2016 |
|
|
|
| 3 |
NCT03730649 |
Not yet recruiting |
Effect of Topical Sulforaphane on Skin Aging and With Ultraviolet and Visible Light Exposure |
|
- Drug: Sulforaphane (broccoli sprout extract)
- Radiation: UV or visible light
|
Interventional
|
Early Phase 1 |
|
Other |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Prevention
|
- keratin 16 presence as determined by immunofluorescence assay
- keratin 17 presence as determined by immunofluorescence assay
- keratin 16 fold change as determined by Reverse Transcription Polymerase Chain Reaction (RT-PCR)
- (and 2 more...)
|
120 |
All |
18 Years and older (Adult, Older Adult) |
NCT03730649 |
IRB00184806 |
|
July 2019 |
December 2024 |
December 2024 |
November 5, 2018 |
May 13, 2019 |
|
- Cutaneous Translational Research Program, Department of Dermatology, Johns Hopkins University School of Medicine
Baltimore, Maryland, United States
|
|
| 4 |
NCT02909959 |
Recruiting |
Sulforaphane for the Treatment of Young Men With Autism Spectrum Disorder |
- Autism Spectrum Disorder
- Autistic Disorder
- Neurodevelopmental Disorder
- Childhood Developmental Disorders, Pervasive
|
- Drug: Sulforaphane
- Drug: Placebo
|
Interventional
|
Phase 2 |
- University of North Carolina, Chapel Hill
- North Carolina Translational and Clinical Sciences Institute
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Change in Social Responsiveness Scale-2 (SRS-2) total scores from baseline to weeks 4, 8, 12 and 16.
- Change in SRS-2 subscale scores (Social Awareness, Social Cognition, Social Communication, Social Motivation, and Restricted Interests/ Repetitive Behaviors) from baseline to weeks 4, 8, 12 and 16.
- Change in Aberrant Behavior Checklist (ABC) subscale scores (Social Withdrawal, Hyperactivity, Inappropriate Speech, Stereotypy, and Irritability) from baseline to weeks 4, 8, 12, and 16.
- (and 9 more...)
|
54 |
Male |
13 Years to 30 Years (Child, Adult) |
NCT02909959 |
16-2059
5KL2TR001109-05 |
|
March 1, 2017 |
November 2019 |
November 2019 |
September 21, 2016 |
May 17, 2018 |
|
- Carolina Institute for Developmental Disabilities, University of North Carolina School of Medicine
Carrboro, North Carolina, United States
|
|
| 5 |
NCT03232138 |
Recruiting |
Clinical Trial of Lung Cancer Chemoprevention With Sulforaphane in Former Smokers |
|
- Dietary Supplement: Sulforaphane
- Drug: Placebo
|
Interventional
|
Phase 2 |
- Jian-Min Yuan, MD
- National Cancer Institute (NCI)
- University of Pittsburgh
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Prevention
|
- Bronchial dysplasia index
- Cell proliferation marker Ki-67
- Apoptosis markers including caspase-3 and TUNEL
- (and 4 more...)
|
72 |
All |
55 Years to 75 Years (Adult, Older Adult) |
NCT03232138 |
16-135
R01CA213123 |
|
January 25, 2018 |
September 30, 2021 |
September 30, 2022 |
July 27, 2017 |
April 30, 2019 |
|
- UPMC Hillman Cancer Center
Pittsburgh, Pennsylvania, United States
|
|
| 6 |
NCT02677051 |
Recruiting |
Sulforaphane in a New Jersey (NJ) Population of Individuals With Autism |
- Autism
- Autistic Disorder
- Autism Spectrum Disorder
- Autistic Behavior
|
- Drug: Sulforaphane
- Drug: Placebo
|
Interventional
|
Phase 2 |
- Rutgers, The State University of New Jersey
- Rowan University
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Change in Aberrant Behavior Checklist (ABC) scores.
- Change in Social Responsiveness Scale (SRS) scores.
- Clinical Global Impression Severity Scale (CGI-S).
- (and 4 more...)
|
40 |
Male |
13 Years to 30 Years (Child, Adult) |
NCT02677051 |
Pro20120001884
CAUT15APL013 |
|
February 2016 |
December 2018 |
January 2022 |
February 9, 2016 |
December 13, 2018 |
|
- Rutgers University - Staged Research Building
Piscataway, New Jersey, United States
|
|
| 7 |
NCT02879110 |
Recruiting |
A 12-weeks Study to Evaluate Sulforaphane in Treatment of Autism Spectrum Disorder |
|
- Dietary Supplement: Sulforaphane
- Other: Placebo
|
Interventional
|
Not Applicable |
- Central South University
- Davis family funding
- University of California
- University of Illinois at Chicago
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- The change of social impairments of children with autism spectrum disorder
- The change of rigid interests and behaviors of children with autism spectrum disorder
- The change of clinical symptoms of children with autism spectrum
- (and 16 more...)
|
120 |
All |
3 Years to 15 Years (Child) |
NCT02879110 |
ASD201512 |
|
August 2016 |
August 2019 |
August 2019 |
August 25, 2016 |
November 27, 2018 |
|
- Guangzhou Huiai Hospital
Guangzhou, Guangdong, China - The second Xiangya hospital of central south university
Changsha, Hunan, China
|
|
| 8 |
NCT03517995 |
Not yet recruiting |
Randomized, Phase II Clinical Trial of Sulforaphane in Bladder Cancer Chemoprevention |
- Bladder Cancer
- Bladder Tumor
- Urothelial Carcinoma
|
- Drug: Sulforaphane Administration
- Other: Placebo Administration
- Procedure: Standard of Care Surgery
|
Interventional
|
Phase 2 |
- H. Lee Moffitt Cancer Center and Research Institute
- National Institutes of Health (NIH)
- Johns Hopkins University
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Care Provider, Investigator)
- Primary Purpose: Prevention
|
- Magnitude of Change
- Effectiveness of Sulforaphane vs. Placebo
- Occurrence of Adverse Events per Study Arm
- (and 4 more...)
|
135 |
All |
18 Years and older (Adult, Older Adult) |
NCT03517995 |
MCC-19574 |
|
September 2019 |
December 2021 |
December 2022 |
May 8, 2018 |
April 3, 2019 |
|
- H. Lee Moffitt Cancer Center and Research Institute
Tampa, Florida, United States - James A. Haley Veteran's Administration Hospital
Tampa, Florida, United States
|
|
| 9 |
NCT03878368 |
Not yet recruiting |
Broccoli In Osteoarthritis |
|
- Dietary Supplement: Sulforaphane
- Dietary Supplement: Placebo
|
Interventional
|
Not Applicable |
- University of East Anglia
- University of Leeds
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- WOMAC (Western Ontario and McMaster Universities Arthritis Index)
- WOMAC (Western Ontario and McMaster Universities Arthritis Index): Pain
- WOMAC (Western Ontario and McMaster Universities Arthritis Index): Physical Function
- (and 9 more...)
|
64 |
All |
50 Years and older (Adult, Older Adult) |
NCT03878368 |
BRIO Protocol V1.0 (22 |
BRIO |
May 1, 2019 |
April 30, 2020 |
June 1, 2020 |
March 18, 2019 |
March 20, 2019 |
|
|
|
| 10 |
NCT03932136 |
Recruiting |
Decreasing Risk of Psychosis by Sulforaphane (DROPS Trial) |
- Clinical High Risk Syndrome of Psychosis
|
- Dietary Supplement: Sulforaphane
- Combination Product: Placebo
|
Interventional
|
Phase 3 |
- Shanghai Jiao Tong University School of Medicine
- Shanghai Xuhui District Mental Health Center
- Shanghai Pudong Nanhui Mental Health Center
- (and 4 more...)
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Prevention
|
- Psychosis conversion rate
- Psychotic level symptoms
- Predicted risk of psychosis
- (and 4 more...)
|
300 |
All |
15 Years to 45 Years (Child, Adult) |
NCT03932136 |
03 |
|
April 1, 2018 |
September 30, 2020 |
December 30, 2020 |
April 30, 2019 |
May 7, 2019 |
|
- Guangzhou Psychiatric Hospital
Guangzhou, Guangdong, China - Second Xiangya Hospital of Central South University
Changsha, Hunan, China - Suzhou Psychiatric Hospital
Suzhou, Jiangsu, China - (and 3 more...)
|
|
| 11 |
NCT03665922 |
Recruiting |
Biomarkers of Sulforaphane/Broccoli Sprout Extract in Prostate Cancer |
|
- Dietary Supplement: BroccoMax®
- Other: Placebo
|
Interventional
|
Not Applicable |
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Investigator, Outcomes Assessor)
- Primary Purpose: Basic Science
|
- Palmitic Acid Reduction
- Evaluation of safety of BroccoMax® (side effects or adverse events)
- Serum SFN levels
- (and 6 more...)
|
40 |
Male |
18 Years to 90 Years (Adult, Older Adult) |
NCT03665922 |
PRO18040423 |
|
May 1, 2019 |
June 15, 2023 |
January 15, 2024 |
September 11, 2018 |
May 24, 2019 |
|
- Shadyside Urology
Pittsburgh, Pennsylvania, United States
|
|
| 12 |
NCT03289832 |
Recruiting |
Effect of Orally Delivered Phytochemicals on Aging and Inflammation in the Skin |
|
- Dietary Supplement: Crucera-SGS
- Dietary Supplement: Meriva 500-SF
|
Interventional
|
Not Applicable |
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Investigator, Outcomes Assessor)
- Primary Purpose: Prevention
|
- Change in Erythema 1 Day After UV Exposure
- Change in Erythema 2 Days After UV Exposure
- Change in Erythema 3 Days After UV Exposure
- (and 8 more...)
|
18 |
All |
18 Years to 70 Years (Adult, Older Adult) |
NCT03289832 |
IRB00117754 |
|
September 25, 2017 |
September 22, 2019 |
December 1, 2019 |
September 21, 2017 |
December 20, 2018 |
|
- Johns Hopkins
Baltimore, Maryland, United States
|
|
| 13 |
NCT03763240 |
Recruiting |
BSE on Blood Glucose |
|
- Dietary Supplement: BSE
- Dietary Supplement: Placebo
|
Interventional
|
Not Applicable |
- Region Skane
- Göteborg University
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- The primary effect variable is venous fasting blood glucose.
|
100 |
All |
35 Years to 75 Years (Adult, Older Adult) |
NCT03763240 |
BSE |
|
September 1, 2018 |
December 1, 2020 |
December 1, 2020 |
December 4, 2018 |
December 4, 2018 |
|
- Gothia Forum
Gothenburg, Sweden
|
|
| 14 |
NCT03649802 |
Not yet recruiting |
Vitamin D and Arterial Stiffness in Elderly |
- Vitamin D Deficiency
- Arterial Stiffness
|
- Dietary Supplement: Low dose vitamin D3
- Dietary Supplement: High dose vitamin D3
|
Interventional
|
Phase 2 |
- Texas Tech University Health Sciences Center
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- Carotid-femoral pulse wave velocity measured by equipment provided by Complior pulse wave analysis
- 24 hour BP ambulatory monitoring
- Heart rate variability
- Plasma sulphoraphane and F2-isoprostanes. Isoprostanes will be measured by gas chromatography mass spectrometry and sulphoraphane will be measured using LC-MS/MS techniques
|
52 |
All |
65 Years to 89 Years (Older Adult) |
NCT03649802 |
L18-174 |
|
June 1, 2019 |
December 31, 2021 |
December 31, 2021 |
August 28, 2018 |
January 29, 2019 |
|
- Texas Tech University Health Sciences Center
Lubbock, Texas, United States
|
|
| 15 |
NCT02614742 |
Recruiting |
SFX01 After Subarachnoid Haemorrhage |
- Subarachnoid Hemorrhage, Spontaneous
|
- Drug: SFX-01
- Drug: Placebo
|
Interventional
|
Phase 2 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Number of participants with treatment-related adverse events as assessed by Common Toxicity Criteria
- Maximum CSF Concentration [Cmax],
- Number of participants with treatment related reduction in middle cerebral artery (MCA) peak flow velocity following Subarachnoid Haemorrhage (SAH) measured by trans cranial doppler ultrasound
- (and 5 more...)
|
90 |
All |
18 Years to 80 Years (Adult, Older Adult) |
NCT02614742 |
EVG001SAH
2014-003284-38 |
SAS |
April 2016 |
March 2019 |
April 2019 |
November 25, 2015 |
August 2, 2018 |
|
- Southampton General Hospital
Southampton, Hampshire, United Kingdom - Queen Elizabeth Hospital
Birmingham, United Kingdom - Western General Hospital
Edinburgh, United Kingdom - The Royal London Hospital
London, United Kingdom
|
|
| 16 |
NCT03182959 |
Recruiting |
Broccoli Sprout Extract in Preventing Recurrence in Patients With Tobacco-Related Head and Neck Squamous Cell Cancer |
- HNSCC
- Head and Neck Cancer
- Head and Neck Squamous Cell Carcinoma
- (and 5 more...)
|
|
Interventional
|
Early Phase 1 |
- University of Arizona
- National Cancer Institute (NCI)
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: None (Open Label)
- Primary Purpose: Prevention
|
- Determine whether Avmacol® results in acute and/or sustained induction of NRF2 target gene transcripts in the oral mucosa of patients who have been curatively treated for a tobacco-related HNSCC.
- Determine whether NRF2 target protein expression is upregulated by Avmacol® in the oral mucosa.
- Evaluate for a dose-response relationship between Avmacol® dose and quantitative change in candidate NRF2 pathway biomarkers in oral mucosa.
- (and 10 more...)
|
36 |
All |
18 Years and older (Adult, Older Adult) |
NCT03182959 |
1612032762
5P50CA097190 |
|
April 24, 2017 |
December 31, 2019 |
December 31, 2019 |
June 9, 2017 |
November 22, 2018 |
|
- The University of Arizona Cancer Center
Tucson, Arizona, United States
|
|
| 17 |
NCT03402230 |
Recruiting |
Broccoli Sprout/Broccoli Seed Extract Supplement in Decreasing Toxicity in Heavy Smokers |
- Current Every Day Smoker
- Tobacco Smoking
|
- Drug: Broccoli Sprout/Broccoli Seed Extract Supplement
- Other: Laboratory Biomarker Analysis
- Other: Questionnaire Administration
|
Interventional
|
Early Phase 1 |
- National Cancer Institute (NCI)
|
NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Prevention
|
- Change in urinary excretion of the mercapturic acid of benzene
- Changes in the urinary excretion of the mercapturic acids of acrolein and crotonaldehyde
- Urinary excretion of the mercapturic acids of tobacco carcinogens
- (and 3 more...)
|
61 |
All |
18 Years and older (Adult, Older Adult) |
NCT03402230 |
NCI-2017-02406
N01-CN-2012-00031
1711022046
UAZ2017-09-02
N01CN00031
P30CA023074 |
|
February 20, 2018 |
November 30, 2020 |
November 30, 2020 |
January 18, 2018 |
June 5, 2019 |
|
- Banner University Medical Center - Tucson
Tucson, Arizona, United States
|
|
Create an RSS feed from your search for:
Download the search results for: